Neurocrine Biosciences Stock Today
| NBIX Stock | USD 125.00 1.71 1.39% |
Performance0 of 100
| Odds Of DistressLess than 1
|
Neurocrine Biosciences is trading at 125.00 as of the 21st of November 2024; that is 1.39 percent increase since the beginning of the trading day. The stock's open price was 123.29. Neurocrine Biosciences has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on September 18, 2024, Representative Michael McCaul of US Congress acquired under $15k worth of Neurocrine Biosciences's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of May 1996 | Category Healthcare | Classification Health Care |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California. Neurocrine Bioscienc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 101.25 M outstanding shares of which 2.48 M shares are now shorted by private and institutional investors with about 2.86 trading days to cover. More on Neurocrine Biosciences
Moving together with Neurocrine Stock
| 0.77 | VRAX | Virax Biolabs Group | PairCorr |
| 0.63 | VRPX | Virpax Pharmaceuticals | PairCorr |
| 0.68 | DYN | Dyne Therapeutics | PairCorr |
Moving against Neurocrine Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Neurocrine Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Kevin Gorman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Obamacare Repeal (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Obamacare Repeal, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNeurocrine Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neurocrine Biosciences' financial leverage. It provides some insight into what part of Neurocrine Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neurocrine Biosciences (NBIX) is traded on NASDAQ Exchange in USA. It is located in 12780 El Camino Real, San Diego, CA, United States, 92130 and employs 1,700 people. Neurocrine Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 12.48 B. Neurocrine Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 101.25 M outstanding shares of which 2.48 M shares are now shorted by private and institutional investors with about 2.86 trading days to cover.
Neurocrine Biosciences currently holds about 799.4 M in cash with 389.9 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.31.
Check Neurocrine Biosciences Probability Of Bankruptcy
Ownership AllocationNeurocrine Biosciences maintains a total of 101.25 Million outstanding shares. The majority of Neurocrine Biosciences outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neurocrine Biosciences to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neurocrine Biosciences. Please pay attention to any change in the institutional holdings of Neurocrine Biosciences as this could imply that something significant has changed or is about to change at the company. On September 18, 2024, Representative Michael McCaul of US Congress acquired under $15k worth of Neurocrine Biosciences's common stock.
Check Neurocrine Ownership Details
Neurocrine Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Aqr Capital Management Llc | 2024-06-30 | 1.2 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.1 M | |
| Armistice Capital, Llc | 2024-06-30 | 978.5 K | |
| Hhg Plc | 2024-06-30 | 971.2 K | |
| Dsm Capital Partners Llc | 2024-09-30 | 944.2 K | |
| Brown Advisory Holdings Inc | 2024-09-30 | 942.1 K | |
| Rock Springs Capital Management Lp | 2024-06-30 | 940 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 934.4 K | |
| Braidwell Lp | 2024-09-30 | 917.7 K | |
| Blackrock Inc | 2024-06-30 | 14.2 M | |
| Vanguard Group Inc | 2024-09-30 | 10 M |
Neurocrine Biosciences Historical Income Statement
Neurocrine Stock Against Markets
Neurocrine Biosciences Corporate Management
| Julie Cooke | Chief People Officer | Profile | |
| Matthew Abernethy | Chief Officer | Profile | |
| Eric Benevich | Chief Commercial Officer | Profile | |
| Darin Lippoldt | Chief Legal Officer | Profile | |
| Jude Onyia | Chief Officer | Profile | |
| Dimitri Grigoriadis | Chief Research Officer | Profile | |
| Kyle Gano | Chief Business Development Officer | Profile |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.